98%
921
2 minutes
20
Objectives: To investigate clinical features associated with lack of response to MTX in juvenile idiopathic arthritis associated uveitis (JIA-U).
Methods: Clinical records of JIA-U patients were retrospectively reviewed. Differences among variables were assessed by Mann-Whitney and χ2 or Fisher's exact tests as appropriate. Association between predictors and requirement of a biological disease-modifying antirheumatic drug (bDMARD) was evaluated by univariate Cox regression analysis and Kaplan-Meier curves. A multivariable logistic model was applied to estimate strength of association, adjusting for potential confounders.
Results: Data from 99 JIA-U patients treated with MTX were analysed (82.8% female), with a mean follow up of 9.2 years and a mean age at uveitis onset of 5.7 years. In 65 patients (65.7%) at least one bDMARD to control uveitis was required. Children requiring a bDMARD for uveitis had lower age at JIA and uveitis onset, more frequent polyarticular course, higher frequency of bilateral uveitis at onset and higher prevalence of systemic steroids' use. Despite similar frequency of ocular damage at onset, MTX non-responders showed a higher percentage of ocular damage at last visit. Younger age at JIA onset, polyarticular course and a history of systemic steroids' use resulted independent factors associated to lack of response to MTX at Cox regression analysis. Kaplan-Meier curves and the multivariate model confirm the independent role of both polyarticular course and systemic steroids' use.
Conclusions: Younger age at JIA onset, polyarticular course and a history of systemic steroids' use are predictors of a worse response to MTX in JIA-U.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781584 | PMC |
http://dx.doi.org/10.1093/rheumatology/keae079 | DOI Listing |
J Rheumatol 2024; doi: 10.3899/jrheum.2024-0298 Following the initial publication of this article, the study team became aware of additional nonserious adverse events (AEs) that occurred during the long-term extension study.
View Article and Find Full Text PDFAutoimmun Rev
July 2025
Unit of Pediatric Clinical Rheumatology, ASST G. Pini - CTO, Milan, Italy; Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy. Electronic address:
Despite the advancements achieved in modern rheumatology, patients with pediatric-onset rheumatological diseases are still exposed to systemic and/or articular inflammation and corticosteroid treatment, all exerting detrimental effects on the growing skeleton together with the reduced body weight and scarce physical activity that rheumatological patients usually experience. The assessment of bone mass in pediatric subjects carries computational limitations: Dual energy X-ray Absiorptiometry (DXA) underestimates bone mineral density (BMD) especially in case of smaller bone, an instance that occurs frequently in children with rheumatologic conditions due to the high rate of short stature or pubertal delay. The rates of low BMD in juvenile idiopathic arthritis (JIA) patients range between 3 % and 34 %, being higher in systemic and polyarticular JIA; patients with juvenile onset systemic lupus erythematosus (jSLE) present a low BMD in approximately 1/3 of cases.
View Article and Find Full Text PDFJ Rheumatol
August 2025
S. Balevic, MD, PhD, Department of Pediatrics, Duke University, Durham, North Carolina, USA.
Objective: To characterize the demographics, disease characteristics, and treatment patterns of an inception cohort of children with juvenile psoriatic arthritis (JPsA) within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.
Methods: Patients diagnosed with JPsA within 6 months of CARRA registry enrollment were included and observed for up to 24 months. Baseline disease characteristics, treatment history, disease activity measures, and patient-reported outcomes (PROs) were captured at 6-month intervals (± 3 months) at usual care visits during the 24-month period.
Front Med (Lausanne)
May 2025
Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Leg length discrepancy (LLD) refers to a condition where the lower limbs are of unequal length, which can result from various underlying causes. Inflammatory conditions in children, such as monoarticular, pauciarticular or polyarticular juvenile idiopathic arthritis (JIA), can lead to the development of LLD when predominantly affecting one leg. To date, no review has addressed inflammation-induced LLD.
View Article and Find Full Text PDFArthritis Rheumatol
May 2025
Joseph M Sanzari Children's Hospital, Hackensack Meridian School of Medicine, Hackensack, New Jersey.
Objective: To assess the impact of differences in the timing of initial biologic disease-modifying antirheumatic drug (bDMARD) therapy using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Start Time Optimization of biologics in Polyarticular Juvenile Idiopathic Arthritis (JIA) (STOP-JIA) - consensus treatment plans study on outcomes through three years.
Methods: Start Time Optimization of biologics in Polyarticular-JIA participants with CARRA Registry follow-up through three years were eligible. Outcomes included American College of Rheumatology clinically inactive disease (CID) off glucocorticoids, clinical Juvenile Arthritis Disease Activity Score based on 10 joints inactive disease (cJADAS-10-ID) (cJADAS-10-ID: cJADAS-10 ≤ 2.